Skip to main content

Advertisement

Table 3 Frequency of achievement of composite endpoints among study groups

From: Evaluation of the efficacy and safety of lixisenatide add-on treatment to basal insulin therapy among T2DM patients with different body mass indices from GetGoal trials

  BMI <25 kg/m2 BMI 25–<30 kg/m2 BMI 30–<35 kg/m2 BMI ≥35 kg/m2 p value
HbA1c <7 % and no symptomatic hypoglycemia, n (%) 26 (19.6) 58 (26.1) 49 (29.5) 42 (29.8) 0.18
HbA1c <7 % and no severe hypoglycemia, n (%) 47 (35.3) 76 (34.2) 69 (41.6) 65 (46.1) 0.10
HbA1c <7 % and no weight gain, n (%) 31 (23.3) 54 (24.3) 48 (28.9) 49 (34.8) 0.10
HbA1c <7 %, no symptomatic hypoglycemia, and no weight gain, n (%) 16 (12.0) 42 (18.9) 36 (21.7) 29 (20.6) 0.16
HbA1c <7 %, no severe hypoglycemia, and no weight gain, n, (%) 31 (23.3) 54 (24.3) 48 (28.9) 48 (34.0) 0.14
  1. BMI body mass index; Statistical significance was determined by χ2 test